Trial Profile
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Determine the Relative Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
- 23 Feb 2023 According to a Luye Pharma media release, company will submit the New Drug Application (NDA) for this drug to the U.S. Food and Drug Administration (FDA) through the 505(b)(2) pathway.
- 12 Aug 2019 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 Planned End Date changed from 30 Jun 2019 to 26 Jul 2019.